Los Angeles, California 90095


Purpose:

The primary purpose of the Phase I portion of the study is to assess the therapeutic safety and preliminary efficacy of a hematopoietic cell-based gene therapy consisting of autologous CD34+ enriched cells transduced with the therapeutic lentiviral vector, Chim-CD18-WPRE, RP-L201. The primary objectives of the Phase II portion of the study are evaluation of survival, as determined by the proportion of subjects alive at age 2 (24 months) and at least 1-year post-infusion without allogeneic hematopoietic stem cell transplant (HSCT) and characterization of the safety and toxicity associated with the infusion.


Study summary:

This is a pediatric non-randomized open-label Phase I/II clinical trial. The Phase I portion will include a safety evaluation and preliminary assessment of the efficacy of hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the ITGB2 gene in subjects with severe LAD-I. CD34+ cells will be transduced ex vivo with the therapeutic vector followed by cryopreservation. If the number of CD34+ cells that are available for infusion is at least 2x10e6 total CD34+ clells/kg, subjects will undergo myeloablative conditioning with intravenous busulfan. Subjects will then receive infusion of gene-corrected hematopoietic cells approximately 24 hours following the final busulfan dose. The active agent is a self-inactivating lentiviral vector carrying the therapeutic ITGB2 gene, encoding for the human CD18 receptor (β2 integrin subunit). The therapeutic product is the subject's autologous hematopoietic stem cells that have been transduced with the lentiviral vector.


Criteria:

Inclusion Criteria: - A confirmed diagnosis of severe LAD-I as demonstrated by flow cytometry indicating CD18 expression on <2% neutrophils (polymorphonuclear neutrophils (PMNs)). Subjects in which CD18+ PMNs are >2% will be considered eligible with <2% CD11a or CD11b expressing PMNs and if there is a documented ITGB2 mutation and clinical history consistent with LAD-I (or known family history). - At least one (1) prior significant bacterial or fungal infection US NCI CTCAE, v5.0, Grade ≥2). This criterion is not required for subjects with documented family history who meet the above inclusion criteria. - Age ≥3 months. - Considered to be an appropriate candidate for autologous transplantation of hematopoietic stem cells. - A competent custodial parent with legal capacity to execute an institutional review board (IRB)/ethics committee (EC)-approved consent form must be available to participate in the consent process. (Informed assent will be sought from capable subjects, in accordance with the directive of the IRB/EC and with local requirements). - Ability to comply with trial procedures including investigational therapy and follow-up evaluations. Exclusion Criteria: - Availability of a medically-eligible human leukocyte antigen (HLA)-identical sibling donor transplant. Subjects may not be included in this trial as an alternative to a clinically-indicated and feasible HLA-matched sibling donor hematopoietic stem cell transplant. If an HLA-identical sibling is identified, but mobilized peripheral blood or bone marrow hematopoietic stem cell collection is not feasible (for example: donor is in utero, is a newborn from whom cord blood was not collected, or is unable to undergo donation procedure because of medical impairments), then inclusion may be permitted per Investigator discretion. - Hepatic dysfunction as defined by either: - Bilirubin >1.5× the upper limit of normal (ULN) or - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5×ULN. - Renal dysfunction as defined by either Grade 3 or higher abnormalities in serum sodium, potassium, calcium, magnesium or phosphate as defined by NCI CTCAE v5.0, or the requirement for either peritoneal dialysis or hemodialysis. - Pulmonary dysfunction as defined by either: - Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection). - Oxygen saturation (by pulse oximetry) <90%. - Evidence of active metastatic or locoregionally advanced malignancy (including hematologic malignancy) for which survival is anticipated to be less than 3 years. - Serious infections with persistent bloodstream pathogens at time of trial entry. (Subjects with active infections (e.g., unresolved ulcerative lesions, skin or oral infections) are permitted as long as appropriate antibiotic therapy has been (or is being) administered). - Any medical or other contraindication for both leukapheresis and bone marrow harvest procedure, as determined by the treating Investigator. - Any medical or other contraindication for the administration of conditioning therapy, as determined by the treating Investigator. - Significant medical conditions, including documented human immunodeficiency virus (HIV) infection, poorly-controlled diabetes, poorly-controlled hypertension, poorly-controlled cardiac arrhythmia or congestive heart failure; or arterial thromboembolic events (including stroke or myocardial infarction) within the 6 prior months. - Any medical or psychiatric condition that in the opinion of the Investigator renders the subject unfit for trial participation or at higher than acceptable risk for participation.


Study is Available At:


Original ID:

RP-L201-0318


NCT ID:

NCT03812263


Secondary ID:


Study Acronym:


Brief Title:

A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I


Official Title:

Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector Encoding the ITGB2 Gene


Overall Status:

Recruiting


Study Phase:

Phase 1/Phase 2


Genders:

N/A


Minimum Age:

3 Months


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Rocket Pharmaceuticals Inc.


Oversight Authority:

There was an error processing this request


Reasons Why Stopped:


Study Type:

Interventional


Study Design:


Number of Arms:

1


Number of Groups:

0


Total Enrollment:

9


Enrollment Type:

Anticipated


Overall Contact Information

Official Name:Donald B Kohn, MD
Principal Investigator
University of California, Los Angeles
Primary Contact:Donald B Kohn, MD
310-794-1964
DKohn1@mednet.ucla

Study Dates

Start Date:November 30, 2018
Completion Date:February 2023
Completion Type:Anticipated
Primary Completion Date:November 2022
Primary Completion Type:Anticipated
Verification Date:January 2019
Last Changed Date:January 22, 2019
First Received Date:January 18, 2019

Study Outcomes

Outcome Type:Primary Outcome
Measure:Phase I: Number of participants with treatment-related adverse events as assessed by United States (US) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0
Time Frame:2 years
Safety Issues:False
Description:Evaluation of safety associated with treatment with RP-L201
Outcome Type:Primary Outcome
Measure:Phase II: Survival following infusion of RP-L201
Time Frame:2 years
Safety Issues:False
Description:Evaluation of survival as determined by the proportion of subjects alive at age 2 (24 months) and at least 1-year post infusion without allogeneic hematopoietic stem cell transplant
Outcome Type:Primary Outcome
Measure:Phase II: Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0
Time Frame:2 years
Safety Issues:False
Description:Evaluation of safety associated with treatment with RP-L201
Outcome Type:Secondary Outcome
Measure:CD18 expression after infusion of RP-L201
Time Frame:2 years
Safety Issues:False
Description:Determination of the percentage of subjects in whom infusion of RP-L201 results in a change in the percentage of neutrophils expressing CD18 to at least 10%
Outcome Type:Secondary Outcome
Measure:Genetic correction after infusion of RP-L201
Time Frame:2 years
Safety Issues:False
Description:Determination of the percentage of subjects in whom infusion of RP-L201 results in at least 10% of peripheral blood neutrophils carrying the therapeutic Chim-CD18-WPRE lentiviral vector provirus at 6 months post-infusion
Outcome Type:Secondary Outcome
Measure:Incidence of infections after infusion of RP-L201
Time Frame:2 years
Safety Issues:False
Description:Determination of the incidence and severity of bacterial or other infections (subsequent to hematopoietic reconstitution)
Outcome Type:Secondary Outcome
Measure:Assessment of LAD-I-associated neutrophilia after infusion of RP-L201
Time Frame:2 years
Safety Issues:False
Description:Evaluation of change to partially normal or to normal levels of LAD-I-associated neutrophilia
Outcome Type:Secondary Outcome
Measure:Assessment of skin rash or periodontal abnormalities after infusion of RP-L201
Time Frame:2 years
Safety Issues:False
Description:Evaluation of resolution (partial or complete) of any underlying skin rash or periodontal abnormalities
Outcome Type:Secondary Outcome
Measure:Assessment of overall survival after infusion of RP-L201
Time Frame:2 years
Safety Issues:False
Description:Evaluation of overall survival (beyond age 24 months and beyond the initial year subsequent to investigational therapy)

Study Interventions

Intervention Type:Biological
Name:RP-L201
Description:CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
Arm Name:RP-L201

Study Arms

Study Arm Type:Experimental
Arm Name:RP-L201
Description:RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single intravenous infusion

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Rocket Pharmaceuticals Inc.

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


If you would like to be contacted by the clinical trial representative please fill out the form below.